Indications
Treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa)
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Linhaliq
- ATC code
- J01MA02
- Therapeutic area
- Bronchiectasis
- Marketing authorisation holder
- Aradigm Pharmaceuticals Limited
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/004394
EMA designations
- Orphan medicine
- No
- Conditional approval
- No